Skip to content

US · BFRIW · MEDICAL - PHARMACEUTICALS

Biofrontera Inc. (BFRIW) intrinsic value and stock valuation

$0.06as of 2026-09-18 · Mkt cap 11.38M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Biofrontera Inc. DCF and intrinsic value

InvestorsCraft values BFRIW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BFRIW’s statements →

Biofrontera Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Woburn, MA, US biofrontera-us.com

How the business is doing

Fiscal 2025–2019, USD

Revenue
$26.2T-6.8% 5y CAGRd
20252019
Net income
-$-10.98T
20252019
Free cash flow
-$-38.22T
20252019
Total equity
-$-30.18T
20252019

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2019, USD
FYFYFYFYFY
Revenue$41.7T$37.3T$34.1T$28.7T$24.1T
Operating income-$-9.15T-$-17.21T-$-22.68T-$-18.58T-$-25.2T
Net income-$-10.54T-$-17.76T-$-20.13T-$-640B-$-37.71T
EPSd-$-904.51K-$-3.22M-$-13.02M-$-605.49K-$-44.1M
Operating cash flow-$-13.36T-$-10.27T-$-24.9T-$-16.2T-$-26.72T
Capital expenditure-$-2B-$-60B-$-5B-$-38B-$-11B
Free cash flow-$-13.36T-$-10.33T-$-24.9T-$-16.24T-$-26.73T
Total assets$28.6T$22.1T$27.9T$50.9T$53.2T
Total debt$6.16T$4.92T$5.4T$1.35T$0.00
Net debt-$-231B-$-983B$4.06T-$-15.86T-$-24.55T
Total equity$10.5T$4.43T$4.79T$23.9T$11.3T
Cash and short-term investments$6.39T$5.91T$1.42T$27.8T$24.5T
Income statement
FYFYFYFYFY
Revenue$41.7T$37.3T$34.1T$28.7T$24.1T
Cost of revenue$8.9T$18.6T$17.4T$15.2T$12.7T
Gross profit$32.8T$18.7T$16.6T$13.5T$11.4T
Research and development expenses$3.72T$2.09T$77B$0.00$0.00
Selling, general and administrative expenses$38.1T$33.8T$39.1T$35.9T$37.2T
Other expenses$100B$0.00$100B-$-3.8T-$-650B
Operating expenses$42T$35.9T$39.3T$32.1T$36.6T
Cost and expenses$50.9T$54.5T$56.7T$47.3T$49.3T
Interest income$0.00$30B$132B$175B$16B
Interest expense$452B$2.11T$600B$370B$360B
Depreciation and amortization$868B$1.15T$1.06T$1.17T$540B
Ebitda-$-9.19T-$-14.44T-$-18.45T$934B-$-36.76T
Operating income-$-9.15T-$-17.21T-$-22.68T-$-18.58T-$-25.2T
Total other income/expenses, net-$-1.36T-$-527B$2.56T$18T-$-12.46T
Income before tax-$-10.51T-$-17.74T-$-20.12T-$-608B-$-37.66T
Income tax expense$25B$22B$14B$32B$56B
Net income-$-10.54T-$-17.76T-$-20.13T-$-640B-$-37.71T
Weighted average shares outstanding$10.2T$5.52T$1.55T$1.06T$855.2B
Weighted average diluted shares outstanding$11.6T$5.52T$1.55T$1.06T$855.2B
Balance sheet
FYFYFYFYFY
Cash and short-term investments$6.39T$5.91T$1.42T$27.8T$24.5T
Net receivables$7.29T$5.32T$5.16T$7.41T$3.78T
Inventory$1.43T$6.65T$10.9T$7.17T$4.46T
Total current assets$18.1T$20.7T$23.1T$43.1T$46.4T
Property, plant and equipment, net$3.74T$983B$1.75T$1.58T$267B
Goodwill and intangible assets$2.65T$35B$2.63T$3.03T$3.45T
Long-term investments$200B$0.00$0.00$0.00$2.81T
Total non-current assets$10.5T$1.4T$4.86T$7.74T$6.8T
Total assets$28.6T$22.1T$27.9T$50.9T$53.2T
Accounts payable$1.86T$1.86T$8.91T$1.28T$658B
Short-term debt$332B$548B$4.6T$498B$0.00
Deferred revenue$0.00$0.00$0.00$6.94T$3.24T
Total current liabilities$11.9T$12T$18.1T$20.9T$13.8T
Long-term debt$5.83T$4.37T$804B$848B$0.00
Deferred revenue, non-current$0.00$0.00$0.00$2.4T$9.54T
Total non-current liabilities$6.19T$5.65T$5.05T$6.11T$28T
Capital lease obligations$332B$824B$1.5T$1.35T$0.00
Total liabilities$18.1T$17.7T$23.1T$27T$41.9T
Common stock$12B$9B$2B$1B$17B
Retained earnings-$-127.95T-$-117.41T-$-99.65T-$-79.52T-$-78.88T
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$10.5T$4.43T$4.79T$23.9T$11.3T
Total investments$209B$7B$78B$10.5T$2.81T
Total debt$6.16T$4.92T$5.4T$1.35T$0.00
Net debt-$-231B-$-983B$4.06T-$-15.86T-$-24.55T
Cash flow statement
FYFYFYFYFY
Net income-$-10.54T-$-17.76T-$-20.13T-$-640B-$-37.71T
Depreciation and amortization$138B$1.15T$1.06T$1.17T$540B
Stock-based compensation$951B$1.02T$1.05T$1.85T$129B
Change in working capital-$-3.48T$6.21T-$-4.39T$2.79T-$-1.51T
Accounts receivable-$-1.91T-$-313B$4.93T$4.92T-$-12T
Inventory$1.45T$4.23T-$-3.75T-$-2.81T$2.59T
Accounts payable-$-535B-$-1.81T$6.42T$0.00-$-773B
Net cash provided by operating activities-$-13.36T-$-10.27T-$-24.9T-$-16.2T-$-26.72T
Investments in property, plant and equipment-$-2B-$-10B-$-5B-$-38B-$-11B
Acquisitions, net$3T$0.00$0.00$0.00$0.00
Net cash used for investing activities$3T-$-3B$619B-$-5.16T-$-11B
Common stock issued$10.9T$0.00$4.51T$9.39T$29.9T
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.9T$14.8T$8.41T$14T$43.2T
Net change in cash$487B$4.56T-$-15.87T-$-7.33T$16.5T
Cash at end of period$6.59T$6.11T$1.54T$17.4T$24.7T
Operating cash flow-$-13.36T-$-10.27T-$-24.9T-$-16.2T-$-26.72T
Capital expenditure-$-2B-$-60B-$-5B-$-38B-$-11B
Free cash flow-$-13.36T-$-10.33T-$-24.9T-$-16.24T-$-26.73T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Biofrontera Inc.

        Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.

        CEO
        Hermann Lübbert
        Employees
        92
        Beta
        0.80

        Explore

        Frequently asked questions

        What is the intrinsic value of Biofrontera Inc. (BFRIW)?

        InvestorsCraft does not currently publish an intrinsic value for BFRIW. How the IC value is calculated.

        Is BFRIW undervalued?

        InvestorsCraft does not publish an undervaluation signal for BFRIW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.